EpiBiologics vs Insilico Medicine
Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $107M Series B (Jan 2026) co-led by J&J Ventures and Google Ventures. EpiTAC targets membrane and secreted proteins — expanding degradation beyond intracellular-only. EPI-326 entering Phase 1 H1 2026.
About
EpiBiologics develops EpiTAC — a targeted protein degradation platform designed to eliminate membrane and secreted proteins that existing degrader technologies cannot reach. The company raised $107 million in Series B financing in January 2026, co-led by Johnson & Johnson Ventures and Google Ventures, a rare investor pairing that brings both pharma development expertise and computational biology capabilities. The lead program, EPI-326 (an EGFR degrader for non-small cell lung cancer), is entering Phase 1 clinical trials in the first half of 2026.
Insilico Medicine (HKEX: 3696) raised $293M, posted $56.2M revenue in 2025, and inked a $2.75B Eli Lilly deal in 2026 using generative AI to discover drug targets in cancer and CNS.
About
Insilico Medicine is a clinical-stage biotechnology company founded in 2014 that leverages generative AI for drug discovery and development. Headquartered in Boston with offices in Hong Kong and New York, the company has built AI platforms utilizing deep generative models, reinforcement learning, and transformers to discover novel drug targets and generate molecular structures with desired properties. Its pipeline spans cancer, fibrosis, CNS diseases, infectious diseases, autoimmune conditions, and aging-related diseases.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.